Literature DB >> 1382991

Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes.

P Lane1, A Traunecker, S Hubele, S Inui, A Lanzavecchia, D Gray.   

Abstract

To identify the ligand for the B cell-associated antigen CD40, we constructed a chimeric immunoglobulin molecule where the extracellular portion of the CD40 protein replaced the normal immunoglobulin variable region. No binding was detected on resting peripheral blood T cells. However, following T cell activation with phorbol esters and ionomycin, the chimeric protein bound specifically to activated human T cells and precipitated a 35-kDa protein from such cells. The induction of the CD40 ligand was detectable on the cell surface after 1 h, with maximal expression after 8 h of stimulation. The T cells expressing CD40 ligand were predominantly CD4 positive, although a proportion of CD8-positive cells also expressed the protein. There was no particular correlation with CD45 phenotype. Finally, we found that soluble CD40 inhibited T-dependent B cell proliferation. The results are discussed in the context of cognate interactions between B and T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382991     DOI: 10.1002/eji.1830221016

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  75 in total

1.  Systematic characterization of porcine ileal Peyer's patch, II. A role for CD154 on T cells in the positive selection of immature porcine ileal Peyer's patch B cells.

Authors:  J K Andersen; H Takamatsu; L Pullen; R M Parkhouse
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

Authors:  A J Lee; C Haworth; R M Hutchinson; R Patel; R Carter; R F James
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 3.  Life and death within germinal centres: a double-edged sword.

Authors:  Liliana Guzman-Rojas; Jennifer C Sims-Mourtada; Roberto Rangel; Hector Martinez-Valdez
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

4.  A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.

Authors:  B Barnhart; G S Ford; A Bhushan; C Song; L R Covey
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 5.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

Review 6.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 7.  The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39.

Authors:  L S Marshall; A Aruffo; J A Ledbetter; R J Noelle
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

8.  Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions.

Authors:  J M Eris; A Basten; R Brink; K Doherty; M R Kehry; P D Hodgkin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.

Authors:  Mario I Vega; Leopoldo Santos-Argumedo; Sara Huerta-Yepez; Rosendo Luría-Perez; Vianney Ortiz-Navarrete; Armado Isibasi; Cesar R González-Bonilla
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  Humoral immune responses in CD40 ligand-deficient mice.

Authors:  B R Renshaw; W C Fanslow; R J Armitage; K A Campbell; D Liggitt; B Wright; B L Davison; C R Maliszewski
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.